View Financial HealthHuapont Life SciencesLtd 配当と自社株買い配当金 基準チェック /46Huapont Life SciencesLtd配当を支払う会社であり、現在の利回りは11.04%です。主要情報11.0%配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長5.5%次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向130%最近の配当と自社株買いの更新お知らせ • Sep 09Huapont Life Sciences Co.,Ltd. Approves Interim Cash Dividend for the Year 2025Huapont Life Sciences Co.,Ltd. announced that at its EGM held on September 05, 2025, shareholders approved the interim cash dividend of CNY 2.00 per 10 shares for the year 2025.お知らせ • Aug 21Huapont Life Sciences Co.,Ltd. Proposes 2025 Interim Profit Distribution PlanHuapont Life Sciences Co.,Ltd. proposed 2025 interim profit distribution plan Cash dividend/10 shares (tax included) is CNY 2.00000000 per share, at the EGM to be held on September 5, 2025.Declared Dividend • May 30Dividend of CN¥0.22 announcedDividend of CN¥0.22 is the same as last year. Ex-date: 3rd June 2024 Payment date: 3rd June 2024 Dividend yield will be 4.8%, which is higher than the industry average of 2.6%. Sustainability & Growth Dividend is not covered by earnings (155% earnings payout ratio) nor is it covered by cash flows (130% cash payout ratio). The dividend has increased by an average of 6.2% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 73% to bring the payout ratio under control. However, EPS has declined by 11% over the last 5 years so the company would need to reverse this trend.お知らせ • May 29Huapont Life Sciences Co.,Ltd Implements Final Cash Dividend for 2023, Payable on June 03, 2024Huapont Life Sciences Co.,Ltd implemented final cash dividend of CNY 2.20000000 per 10 A shares (tax included) for 2023. Record date: 31 May 2024; Ex-date: 03 June 2024; Payment date: 03 June 2024. 10 percent withholding tax on cash dividend will be deducted in CNY within the cash dividend receivable. Please refer to below details: Tax on cash dividend/10 shares: CNY 0.22000000 (10% x CNY 2.20000000) Net cash dividend/10 shares after tax: CNY 1.98000000 (CNY 2.20000000- CNY 0.22000000).お知らせ • May 26Huapont Life Sciences Co.,Ltd Approves Cash Dividend for 2023Huapont Life Sciences Co.,Ltd at its Annual General Meeting held on 23 May 2024 approved the cash dividend of CNY 2.20000000 per 10 shares (tax included) for 2023.お知らせ • Jun 09Huapont Life Sciences Co.,Ltd Announces Final Dividend on Share A for 2022, Payable on June 15, 2023Huapont Life Sciences Co.,Ltd announced final Cash dividend/10 shares (tax included): CNY 2.20000000 on share A for 2022. Record date: 14 June 2023, Ex-date: 15 June 2023, Payment date: 15 June 2023.すべての更新を表示Recent updatesBoard Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 5 highly experienced directors. 2 independent directors (4 non-independent directors). Independent Director Zhonghai Liu was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Apr 23Huapont Life Sciences Co.,Ltd., Annual General Meeting, May 15, 2026Huapont Life Sciences Co.,Ltd., Annual General Meeting, May 15, 2026, at 13:30 China Standard Time. Location: No. 69, Xingguang Avenue, Renhe, Yubei District, Chongqing Chinaお知らせ • Mar 31Huapont Life Sciences Co.,Ltd. to Report Q1, 2026 Results on Apr 25, 2026Huapont Life Sciences Co.,Ltd. announced that they will report Q1, 2026 results on Apr 25, 2026お知らせ • Dec 31Huapont Life Sciences Co.,Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026Huapont Life Sciences Co.,Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026お知らせ • Sep 30Huapont Life Sciences Co.,Ltd. to Report Q3, 2025 Results on Oct 29, 2025Huapont Life Sciences Co.,Ltd. announced that they will report Q3, 2025 results on Oct 29, 2025お知らせ • Sep 09Huapont Life Sciences Co.,Ltd. Approves Interim Cash Dividend for the Year 2025Huapont Life Sciences Co.,Ltd. announced that at its EGM held on September 05, 2025, shareholders approved the interim cash dividend of CNY 2.00 per 10 shares for the year 2025.お知らせ • Aug 21Huapont Life Sciences Co.,Ltd. Proposes 2025 Interim Profit Distribution PlanHuapont Life Sciences Co.,Ltd. proposed 2025 interim profit distribution plan Cash dividend/10 shares (tax included) is CNY 2.00000000 per share, at the EGM to be held on September 5, 2025.お知らせ • Jul 02Huapont Life Sciences Co.,Ltd. to Report First Half, 2025 Results on Aug 20, 2025Huapont Life Sciences Co.,Ltd. announced that they will report first half, 2025 results on Aug 20, 2025お知らせ • May 16Huapont Life Sciences Co.,Ltd. Approves the Election of Zhang Songshan as Non-Independent DirectorHuapont Life Sciences Co.,Ltd. at its Annual General Meeting held on 14 May 2025 approved the election of Zhang Songshan as non-independent director.お知らせ • Apr 23Huapont Life Sciences Co.,Ltd., Annual General Meeting, May 14, 2025Huapont Life Sciences Co.,Ltd., Annual General Meeting, May 14, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Chongqing Chinaお知らせ • Mar 31Huapont Life Sciences Co.,Ltd. to Report Q1, 2025 Results on Apr 23, 2025Huapont Life Sciences Co.,Ltd. announced that they will report Q1, 2025 results on Apr 23, 2025お知らせ • Dec 31Huapont Life Sciences Co.,Ltd. to Report Fiscal Year 2024 Results on Apr 19, 2025Huapont Life Sciences Co.,Ltd. announced that they will report fiscal year 2024 results on Apr 19, 2025Reported Earnings • Oct 29Third quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.059 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.07 (up from CN¥0.059 in 3Q 2023). Revenue: CN¥2.99b (flat on 3Q 2023). Net income: CN¥138.5m (up 18% from 3Q 2023). Profit margin: 4.6% (up from 3.9% in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CN¥4.75, the stock trades at a trailing P/E ratio of 41x. Average trailing P/E is 30x in the Chemicals industry in China. Total loss to shareholders of 22% over the past three years.お知らせ • Sep 30Huapont Life Sciences Co.,Ltd. to Report Q3, 2024 Results on Oct 29, 2024Huapont Life Sciences Co.,Ltd. announced that they will report Q3, 2024 results on Oct 29, 2024Reported Earnings • Aug 31Second quarter 2024 earnings released: EPS: CN¥0.08 (vs CN¥0.11 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.08 (down from CN¥0.11 in 2Q 2023). Revenue: CN¥3.01b (up 3.9% from 2Q 2023). Net income: CN¥158.0m (down 25% from 2Q 2023). Profit margin: 5.3% (down from 7.3% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.お知らせ • Jun 29Huapont Life Sciences Co.,Ltd to Report First Half, 2024 Results on Aug 31, 2024Huapont Life Sciences Co.,Ltd announced that they will report first half, 2024 results on Aug 31, 2024Declared Dividend • May 30Dividend of CN¥0.22 announcedDividend of CN¥0.22 is the same as last year. Ex-date: 3rd June 2024 Payment date: 3rd June 2024 Dividend yield will be 4.8%, which is higher than the industry average of 2.6%. Sustainability & Growth Dividend is not covered by earnings (155% earnings payout ratio) nor is it covered by cash flows (130% cash payout ratio). The dividend has increased by an average of 6.2% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 73% to bring the payout ratio under control. However, EPS has declined by 11% over the last 5 years so the company would need to reverse this trend.お知らせ • May 29Huapont Life Sciences Co.,Ltd Implements Final Cash Dividend for 2023, Payable on June 03, 2024Huapont Life Sciences Co.,Ltd implemented final cash dividend of CNY 2.20000000 per 10 A shares (tax included) for 2023. Record date: 31 May 2024; Ex-date: 03 June 2024; Payment date: 03 June 2024. 10 percent withholding tax on cash dividend will be deducted in CNY within the cash dividend receivable. Please refer to below details: Tax on cash dividend/10 shares: CNY 0.22000000 (10% x CNY 2.20000000) Net cash dividend/10 shares after tax: CNY 1.98000000 (CNY 2.20000000- CNY 0.22000000).お知らせ • May 26Huapont Life Sciences Co.,Ltd Approves Cash Dividend for 2023Huapont Life Sciences Co.,Ltd at its Annual General Meeting held on 23 May 2024 approved the cash dividend of CNY 2.20000000 per 10 shares (tax included) for 2023.お知らせ • Apr 29Huapont Life Sciences Co.,Ltd, Annual General Meeting, May 23, 2024Huapont Life Sciences Co.,Ltd, Annual General Meeting, May 23, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Chongqing ChinaReported Earnings • Apr 27First quarter 2024 earnings released: EPS: CN¥0.079 (vs CN¥0.09 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.079 (down from CN¥0.09 in 1Q 2023). Revenue: CN¥2.92b (down 2.0% from 1Q 2023). Net income: CN¥155.6m (down 12% from 1Q 2023). Profit margin: 5.3% (down from 6.0% in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.お知らせ • Mar 30Huapont Life Sciences Co.,Ltd to Report Q1, 2024 Results on Apr 27, 2024Huapont Life Sciences Co.,Ltd announced that they will report Q1, 2024 results on Apr 27, 2024Valuation Update With 7 Day Price Move • Feb 12Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥4.50, the stock trades at a trailing P/E ratio of 40.3x. Average trailing P/E is 25x in the Chemicals industry in China. Total returns to shareholders of 2.4% over the past three years.お知らせ • Dec 29+ 1 more updateHuapont Life Sciences Co.,Ltd to Report Fiscal Year 2023 Results on Apr 27, 2024Huapont Life Sciences Co.,Ltd announced that they will report fiscal year 2023 results on Apr 27, 2024Board Change • Dec 22Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Zhonghai Liu was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Dec 13+ 1 more updateHuapont Life Sciences Co.,Ltd(SZSE:002004) dropped from Shenzhen Stock Exchange Component IndexHuapont-Nutrichem Co., Ltd. has been removed from Shenzhen Stock Exchange Component Index.Reported Earnings • Nov 01Third quarter 2023 earnings released: EPS: CN¥0.059 (vs CN¥0.079 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.059 (down from CN¥0.079 in 3Q 2022). Revenue: CN¥2.98b (down 14% from 3Q 2022). Net income: CN¥117.8m (down 25% from 3Q 2022). Profit margin: 3.9% (down from 4.5% in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.Reported Earnings • Aug 29Second quarter 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.20 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.11 (down from CN¥0.20 in 2Q 2022). Revenue: CN¥2.89b (down 12% from 2Q 2022). Net income: CN¥210.0m (down 46% from 2Q 2022). Profit margin: 7.3% (down from 12% in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.お知らせ • Jun 09Huapont Life Sciences Co.,Ltd Announces Final Dividend on Share A for 2022, Payable on June 15, 2023Huapont Life Sciences Co.,Ltd announced final Cash dividend/10 shares (tax included): CNY 2.20000000 on share A for 2022. Record date: 14 June 2023, Ex-date: 15 June 2023, Payment date: 15 June 2023.お知らせ • May 19Huapont Life Sciences Co.,Ltd Approves Final Cash Dividend Per 10 Shares for 2022Huapont Life Sciences Co.,Ltd approved final cash dividend per 10 shares (tax included) of CNY 2.20000000 for the year 2022 at its Annual General Meeting of 2022 on 17 May 2023.Reported Earnings • Apr 28First quarter 2023 earnings released: EPS: CN¥0.09 (vs CN¥0.085 in 1Q 2022)First quarter 2023 results: EPS: CN¥0.09 (up from CN¥0.085 in 1Q 2022). Revenue: CN¥2.98b (down 13% from 1Q 2022). Net income: CN¥177.1m (up 5.0% from 1Q 2022). Profit margin: 6.0% (up from 5.0% in 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has remained flat.Buying Opportunity • Apr 27Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 1.1%. The fair value is estimated to be CN¥6.66, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last year. Earnings per share has grown by 32%.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. 3 independent directors (5 non-independent directors). Independent Director Shuang Liang was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Oct 31Third quarter 2022 earnings released: EPS: CN¥0.079 (vs CN¥0.08 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.079 (down from CN¥0.08 in 3Q 2021). Revenue: CN¥3.48b (up 21% from 3Q 2021). Net income: CN¥157.1m (down 6.2% from 3Q 2021). Profit margin: 4.5% (down from 5.8% in 3Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.Reported Earnings • Aug 20Second quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.12 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.20 (up from CN¥0.12 in 2Q 2021). Revenue: CN¥3.30b (up 13% from 2Q 2021). Net income: CN¥391.3m (up 69% from 2Q 2021). Profit margin: 12% (up from 7.9% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 10% per year.Reported Earnings • May 02First quarter 2022 earnings released: EPS: CN¥0.085 (vs CN¥0.06 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.085 (up from CN¥0.06 in 1Q 2021). Revenue: CN¥3.40b (up 21% from 1Q 2021). Net income: CN¥168.6m (up 39% from 1Q 2021). Profit margin: 5.0% (up from 4.3% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. 3 independent directors (5 non-independent directors). Independent Director Shuang Liang was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Feb 27Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: CN¥0.34 (up from CN¥0.33 in FY 2020). Revenue: CN¥12.4b (up 14% from FY 2020). Net income: CN¥670.0m (up 2.8% from FY 2020). Profit margin: 5.4% (down from 6.0% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.2%. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Nov 23Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥7.40, the stock trades at a trailing P/E ratio of 22.3x. Average trailing P/E is 34x in the Chemicals industry in China. Total returns to shareholders of 65% over the past three years.Reported Earnings • Oct 31Third quarter 2021 earnings released: EPS CN¥0.08 (vs CN¥0.10 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: CN¥2.88b (up 6.4% from 3Q 2020). Net income: CN¥167.5m (down 15% from 3Q 2020). Profit margin: 5.8% (down from 7.3% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 7% per year.Valuation Update With 7 Day Price Move • Sep 29Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to CN¥7.25, the stock trades at a trailing P/E ratio of 20.9x. Average trailing P/E is 31x in the Chemicals industry in China. Total returns to shareholders of 68% over the past three years.Valuation Update With 7 Day Price Move • Sep 08Investor sentiment improved over the past weekAfter last week's 26% share price gain to CN¥7.44, the stock trades at a trailing P/E ratio of 16.8x. Average trailing P/E is 34x in the Chemicals industry in China. Total returns to shareholders of 72% over the past three years.Reported Earnings • Aug 30Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.12 in 2Q 2020)The company reported a poor second quarter result with weaker earnings and profit margins, although revenues were flat. Second quarter 2021 results: Revenue: CN¥2.93b (flat on 2Q 2020). Net income: CN¥231.5m (down 1.3% from 2Q 2020). Profit margin: 7.9% (down from 8.0% in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.Reported Earnings • Apr 29First quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.04 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥2.82b (up 25% from 1Q 2020). Net income: CN¥121.6m (up 47% from 1Q 2020). Profit margin: 4.3% (up from 3.7% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.Reported Earnings • Apr 01Full year 2020 earnings released: EPS CN¥0.33 (vs CN¥0.31 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2020 results: Revenue: CN¥10.9b (up 7.8% from FY 2019). Net income: CN¥651.7m (up 5.1% from FY 2019). Profit margin: 6.0% (down from 6.1% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 04Full year 2020 earnings released: EPS CN¥0.33 (vs CN¥0.31 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2020 results: Revenue: CN¥10.9b (up 8.4% from FY 2019). Net income: CN¥652.1m (up 5.1% from FY 2019). Profit margin: 6.0% (down from 6.1% in FY 2019). The decrease in margin was driven by higher expenses.Is New 90 Day High Low • Jan 25New 90-day low: CN¥5.02The company is down 3.0% from its price of CN¥5.19 on 28 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 25% over the same period.Is New 90 Day High Low • Dec 14New 90-day high: CN¥6.06The company is up 14% from its price of CN¥5.32 on 16 September 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 6.0% over the same period.Is New 90 Day High Low • Nov 18New 90-day high: CN¥5.71The company is up 2.0% from its price of CN¥5.62 on 20 August 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 5.0% over the same period.Reported Earnings • Nov 01Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥627.2m, up 19% from the prior year. Total revenue was CN¥10.5b over the last 12 months, up 2.7% from the prior year.Is New 90 Day High Low • Sep 24New 90-day low: CN¥5.18The company is down 2.0% from its price of CN¥5.26 on 24 June 2020. The Chinese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 21% over the same period.決済の安定と成長配当データの取得安定した配当: 002004の配当金支払いは、過去10年間 変動性 が高かった。増加する配当: 002004の配当金は過去10年間にわたって増加しています。配当利回り対市場Huapont Life SciencesLtd 配当利回り対市場002004 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (002004)11.0%市場下位25% (CN)0.4%市場トップ25% (CN)2.0%業界平均 (Chemicals)1.3%アナリスト予想 (002004) (最長3年)n/a注目すべき配当: 002004の配当金 ( 11.04% ) はCN市場の配当金支払者の下位 25% ( 0.37% ) よりも高くなっています。高配当: 002004の配当金 ( 11.04% ) はCN市場 ( 2.01% ) の配当支払者の中で上位 25% に入っています。株主への利益配当収益カバレッジ: 002004は高い 配当性向 ( 129.8% ) のため、配当金の支払いは利益によって十分にカバーされていません。株主配当金キャッシュフローカバレッジ: 002004は合理的な 現金配当性向 ( 58.1% ) を備えているため、配当金の支払いはキャッシュフローによって賄われます。高配当企業の発掘7D1Y7D1Y7D1YCN 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/29 17:06終値2026/05/29 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Huapont Life Sciences Co.,Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Bing GaoChina International Capital Corporation LimitedSissie OuChina Stock Investment Research Co. Ltd. (GZ500..com)Wei MaoEverbright Securities Co. Ltd.4 その他のアナリストを表示
お知らせ • Sep 09Huapont Life Sciences Co.,Ltd. Approves Interim Cash Dividend for the Year 2025Huapont Life Sciences Co.,Ltd. announced that at its EGM held on September 05, 2025, shareholders approved the interim cash dividend of CNY 2.00 per 10 shares for the year 2025.
お知らせ • Aug 21Huapont Life Sciences Co.,Ltd. Proposes 2025 Interim Profit Distribution PlanHuapont Life Sciences Co.,Ltd. proposed 2025 interim profit distribution plan Cash dividend/10 shares (tax included) is CNY 2.00000000 per share, at the EGM to be held on September 5, 2025.
Declared Dividend • May 30Dividend of CN¥0.22 announcedDividend of CN¥0.22 is the same as last year. Ex-date: 3rd June 2024 Payment date: 3rd June 2024 Dividend yield will be 4.8%, which is higher than the industry average of 2.6%. Sustainability & Growth Dividend is not covered by earnings (155% earnings payout ratio) nor is it covered by cash flows (130% cash payout ratio). The dividend has increased by an average of 6.2% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 73% to bring the payout ratio under control. However, EPS has declined by 11% over the last 5 years so the company would need to reverse this trend.
お知らせ • May 29Huapont Life Sciences Co.,Ltd Implements Final Cash Dividend for 2023, Payable on June 03, 2024Huapont Life Sciences Co.,Ltd implemented final cash dividend of CNY 2.20000000 per 10 A shares (tax included) for 2023. Record date: 31 May 2024; Ex-date: 03 June 2024; Payment date: 03 June 2024. 10 percent withholding tax on cash dividend will be deducted in CNY within the cash dividend receivable. Please refer to below details: Tax on cash dividend/10 shares: CNY 0.22000000 (10% x CNY 2.20000000) Net cash dividend/10 shares after tax: CNY 1.98000000 (CNY 2.20000000- CNY 0.22000000).
お知らせ • May 26Huapont Life Sciences Co.,Ltd Approves Cash Dividend for 2023Huapont Life Sciences Co.,Ltd at its Annual General Meeting held on 23 May 2024 approved the cash dividend of CNY 2.20000000 per 10 shares (tax included) for 2023.
お知らせ • Jun 09Huapont Life Sciences Co.,Ltd Announces Final Dividend on Share A for 2022, Payable on June 15, 2023Huapont Life Sciences Co.,Ltd announced final Cash dividend/10 shares (tax included): CNY 2.20000000 on share A for 2022. Record date: 14 June 2023, Ex-date: 15 June 2023, Payment date: 15 June 2023.
Board Change • May 20Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 5 highly experienced directors. 2 independent directors (4 non-independent directors). Independent Director Zhonghai Liu was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Apr 23Huapont Life Sciences Co.,Ltd., Annual General Meeting, May 15, 2026Huapont Life Sciences Co.,Ltd., Annual General Meeting, May 15, 2026, at 13:30 China Standard Time. Location: No. 69, Xingguang Avenue, Renhe, Yubei District, Chongqing China
お知らせ • Mar 31Huapont Life Sciences Co.,Ltd. to Report Q1, 2026 Results on Apr 25, 2026Huapont Life Sciences Co.,Ltd. announced that they will report Q1, 2026 results on Apr 25, 2026
お知らせ • Dec 31Huapont Life Sciences Co.,Ltd. to Report Fiscal Year 2025 Results on Apr 23, 2026Huapont Life Sciences Co.,Ltd. announced that they will report fiscal year 2025 results on Apr 23, 2026
お知らせ • Sep 30Huapont Life Sciences Co.,Ltd. to Report Q3, 2025 Results on Oct 29, 2025Huapont Life Sciences Co.,Ltd. announced that they will report Q3, 2025 results on Oct 29, 2025
お知らせ • Sep 09Huapont Life Sciences Co.,Ltd. Approves Interim Cash Dividend for the Year 2025Huapont Life Sciences Co.,Ltd. announced that at its EGM held on September 05, 2025, shareholders approved the interim cash dividend of CNY 2.00 per 10 shares for the year 2025.
お知らせ • Aug 21Huapont Life Sciences Co.,Ltd. Proposes 2025 Interim Profit Distribution PlanHuapont Life Sciences Co.,Ltd. proposed 2025 interim profit distribution plan Cash dividend/10 shares (tax included) is CNY 2.00000000 per share, at the EGM to be held on September 5, 2025.
お知らせ • Jul 02Huapont Life Sciences Co.,Ltd. to Report First Half, 2025 Results on Aug 20, 2025Huapont Life Sciences Co.,Ltd. announced that they will report first half, 2025 results on Aug 20, 2025
お知らせ • May 16Huapont Life Sciences Co.,Ltd. Approves the Election of Zhang Songshan as Non-Independent DirectorHuapont Life Sciences Co.,Ltd. at its Annual General Meeting held on 14 May 2025 approved the election of Zhang Songshan as non-independent director.
お知らせ • Apr 23Huapont Life Sciences Co.,Ltd., Annual General Meeting, May 14, 2025Huapont Life Sciences Co.,Ltd., Annual General Meeting, May 14, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Chongqing China
お知らせ • Mar 31Huapont Life Sciences Co.,Ltd. to Report Q1, 2025 Results on Apr 23, 2025Huapont Life Sciences Co.,Ltd. announced that they will report Q1, 2025 results on Apr 23, 2025
お知らせ • Dec 31Huapont Life Sciences Co.,Ltd. to Report Fiscal Year 2024 Results on Apr 19, 2025Huapont Life Sciences Co.,Ltd. announced that they will report fiscal year 2024 results on Apr 19, 2025
Reported Earnings • Oct 29Third quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.059 in 3Q 2023)Third quarter 2024 results: EPS: CN¥0.07 (up from CN¥0.059 in 3Q 2023). Revenue: CN¥2.99b (flat on 3Q 2023). Net income: CN¥138.5m (up 18% from 3Q 2023). Profit margin: 4.6% (up from 3.9% in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CN¥4.75, the stock trades at a trailing P/E ratio of 41x. Average trailing P/E is 30x in the Chemicals industry in China. Total loss to shareholders of 22% over the past three years.
お知らせ • Sep 30Huapont Life Sciences Co.,Ltd. to Report Q3, 2024 Results on Oct 29, 2024Huapont Life Sciences Co.,Ltd. announced that they will report Q3, 2024 results on Oct 29, 2024
Reported Earnings • Aug 31Second quarter 2024 earnings released: EPS: CN¥0.08 (vs CN¥0.11 in 2Q 2023)Second quarter 2024 results: EPS: CN¥0.08 (down from CN¥0.11 in 2Q 2023). Revenue: CN¥3.01b (up 3.9% from 2Q 2023). Net income: CN¥158.0m (down 25% from 2Q 2023). Profit margin: 5.3% (down from 7.3% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
お知らせ • Jun 29Huapont Life Sciences Co.,Ltd to Report First Half, 2024 Results on Aug 31, 2024Huapont Life Sciences Co.,Ltd announced that they will report first half, 2024 results on Aug 31, 2024
Declared Dividend • May 30Dividend of CN¥0.22 announcedDividend of CN¥0.22 is the same as last year. Ex-date: 3rd June 2024 Payment date: 3rd June 2024 Dividend yield will be 4.8%, which is higher than the industry average of 2.6%. Sustainability & Growth Dividend is not covered by earnings (155% earnings payout ratio) nor is it covered by cash flows (130% cash payout ratio). The dividend has increased by an average of 6.2% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 73% to bring the payout ratio under control. However, EPS has declined by 11% over the last 5 years so the company would need to reverse this trend.
お知らせ • May 29Huapont Life Sciences Co.,Ltd Implements Final Cash Dividend for 2023, Payable on June 03, 2024Huapont Life Sciences Co.,Ltd implemented final cash dividend of CNY 2.20000000 per 10 A shares (tax included) for 2023. Record date: 31 May 2024; Ex-date: 03 June 2024; Payment date: 03 June 2024. 10 percent withholding tax on cash dividend will be deducted in CNY within the cash dividend receivable. Please refer to below details: Tax on cash dividend/10 shares: CNY 0.22000000 (10% x CNY 2.20000000) Net cash dividend/10 shares after tax: CNY 1.98000000 (CNY 2.20000000- CNY 0.22000000).
お知らせ • May 26Huapont Life Sciences Co.,Ltd Approves Cash Dividend for 2023Huapont Life Sciences Co.,Ltd at its Annual General Meeting held on 23 May 2024 approved the cash dividend of CNY 2.20000000 per 10 shares (tax included) for 2023.
お知らせ • Apr 29Huapont Life Sciences Co.,Ltd, Annual General Meeting, May 23, 2024Huapont Life Sciences Co.,Ltd, Annual General Meeting, May 23, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Chongqing China
Reported Earnings • Apr 27First quarter 2024 earnings released: EPS: CN¥0.079 (vs CN¥0.09 in 1Q 2023)First quarter 2024 results: EPS: CN¥0.079 (down from CN¥0.09 in 1Q 2023). Revenue: CN¥2.92b (down 2.0% from 1Q 2023). Net income: CN¥155.6m (down 12% from 1Q 2023). Profit margin: 5.3% (down from 6.0% in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.
お知らせ • Mar 30Huapont Life Sciences Co.,Ltd to Report Q1, 2024 Results on Apr 27, 2024Huapont Life Sciences Co.,Ltd announced that they will report Q1, 2024 results on Apr 27, 2024
Valuation Update With 7 Day Price Move • Feb 12Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥4.50, the stock trades at a trailing P/E ratio of 40.3x. Average trailing P/E is 25x in the Chemicals industry in China. Total returns to shareholders of 2.4% over the past three years.
お知らせ • Dec 29+ 1 more updateHuapont Life Sciences Co.,Ltd to Report Fiscal Year 2023 Results on Apr 27, 2024Huapont Life Sciences Co.,Ltd announced that they will report fiscal year 2023 results on Apr 27, 2024
Board Change • Dec 22Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Zhonghai Liu was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Dec 13+ 1 more updateHuapont Life Sciences Co.,Ltd(SZSE:002004) dropped from Shenzhen Stock Exchange Component IndexHuapont-Nutrichem Co., Ltd. has been removed from Shenzhen Stock Exchange Component Index.
Reported Earnings • Nov 01Third quarter 2023 earnings released: EPS: CN¥0.059 (vs CN¥0.079 in 3Q 2022)Third quarter 2023 results: EPS: CN¥0.059 (down from CN¥0.079 in 3Q 2022). Revenue: CN¥2.98b (down 14% from 3Q 2022). Net income: CN¥117.8m (down 25% from 3Q 2022). Profit margin: 3.9% (down from 4.5% in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings.
Reported Earnings • Aug 29Second quarter 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.20 in 2Q 2022)Second quarter 2023 results: EPS: CN¥0.11 (down from CN¥0.20 in 2Q 2022). Revenue: CN¥2.89b (down 12% from 2Q 2022). Net income: CN¥210.0m (down 46% from 2Q 2022). Profit margin: 7.3% (down from 12% in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings.
お知らせ • Jun 09Huapont Life Sciences Co.,Ltd Announces Final Dividend on Share A for 2022, Payable on June 15, 2023Huapont Life Sciences Co.,Ltd announced final Cash dividend/10 shares (tax included): CNY 2.20000000 on share A for 2022. Record date: 14 June 2023, Ex-date: 15 June 2023, Payment date: 15 June 2023.
お知らせ • May 19Huapont Life Sciences Co.,Ltd Approves Final Cash Dividend Per 10 Shares for 2022Huapont Life Sciences Co.,Ltd approved final cash dividend per 10 shares (tax included) of CNY 2.20000000 for the year 2022 at its Annual General Meeting of 2022 on 17 May 2023.
Reported Earnings • Apr 28First quarter 2023 earnings released: EPS: CN¥0.09 (vs CN¥0.085 in 1Q 2022)First quarter 2023 results: EPS: CN¥0.09 (up from CN¥0.085 in 1Q 2022). Revenue: CN¥2.98b (down 13% from 1Q 2022). Net income: CN¥177.1m (up 5.0% from 1Q 2022). Profit margin: 6.0% (up from 5.0% in 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has remained flat.
Buying Opportunity • Apr 27Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 1.1%. The fair value is estimated to be CN¥6.66, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last year. Earnings per share has grown by 32%.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. 3 independent directors (5 non-independent directors). Independent Director Shuang Liang was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Oct 31Third quarter 2022 earnings released: EPS: CN¥0.079 (vs CN¥0.08 in 3Q 2021)Third quarter 2022 results: EPS: CN¥0.079 (down from CN¥0.08 in 3Q 2021). Revenue: CN¥3.48b (up 21% from 3Q 2021). Net income: CN¥157.1m (down 6.2% from 3Q 2021). Profit margin: 4.5% (down from 5.8% in 3Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Aug 20Second quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.12 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.20 (up from CN¥0.12 in 2Q 2021). Revenue: CN¥3.30b (up 13% from 2Q 2021). Net income: CN¥391.3m (up 69% from 2Q 2021). Profit margin: 12% (up from 7.9% in 2Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 10% per year.
Reported Earnings • May 02First quarter 2022 earnings released: EPS: CN¥0.085 (vs CN¥0.06 in 1Q 2021)First quarter 2022 results: EPS: CN¥0.085 (up from CN¥0.06 in 1Q 2021). Revenue: CN¥3.40b (up 21% from 1Q 2021). Net income: CN¥168.6m (up 39% from 1Q 2021). Profit margin: 5.0% (up from 4.3% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. 3 independent directors (5 non-independent directors). Independent Director Shuang Liang was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Feb 27Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: CN¥0.34 (up from CN¥0.33 in FY 2020). Revenue: CN¥12.4b (up 14% from FY 2020). Net income: CN¥670.0m (up 2.8% from FY 2020). Profit margin: 5.4% (down from 6.0% in FY 2020). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.2%. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Nov 23Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥7.40, the stock trades at a trailing P/E ratio of 22.3x. Average trailing P/E is 34x in the Chemicals industry in China. Total returns to shareholders of 65% over the past three years.
Reported Earnings • Oct 31Third quarter 2021 earnings released: EPS CN¥0.08 (vs CN¥0.10 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: CN¥2.88b (up 6.4% from 3Q 2020). Net income: CN¥167.5m (down 15% from 3Q 2020). Profit margin: 5.8% (down from 7.3% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 7% per year.
Valuation Update With 7 Day Price Move • Sep 29Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to CN¥7.25, the stock trades at a trailing P/E ratio of 20.9x. Average trailing P/E is 31x in the Chemicals industry in China. Total returns to shareholders of 68% over the past three years.
Valuation Update With 7 Day Price Move • Sep 08Investor sentiment improved over the past weekAfter last week's 26% share price gain to CN¥7.44, the stock trades at a trailing P/E ratio of 16.8x. Average trailing P/E is 34x in the Chemicals industry in China. Total returns to shareholders of 72% over the past three years.
Reported Earnings • Aug 30Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.12 in 2Q 2020)The company reported a poor second quarter result with weaker earnings and profit margins, although revenues were flat. Second quarter 2021 results: Revenue: CN¥2.93b (flat on 2Q 2020). Net income: CN¥231.5m (down 1.3% from 2Q 2020). Profit margin: 7.9% (down from 8.0% in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Apr 29First quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.04 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥2.82b (up 25% from 1Q 2020). Net income: CN¥121.6m (up 47% from 1Q 2020). Profit margin: 4.3% (up from 3.7% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Apr 01Full year 2020 earnings released: EPS CN¥0.33 (vs CN¥0.31 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2020 results: Revenue: CN¥10.9b (up 7.8% from FY 2019). Net income: CN¥651.7m (up 5.1% from FY 2019). Profit margin: 6.0% (down from 6.1% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 04Full year 2020 earnings released: EPS CN¥0.33 (vs CN¥0.31 in FY 2019)The company reported a solid full year result with improved earnings and revenues, although profit margins were weaker. Full year 2020 results: Revenue: CN¥10.9b (up 8.4% from FY 2019). Net income: CN¥652.1m (up 5.1% from FY 2019). Profit margin: 6.0% (down from 6.1% in FY 2019). The decrease in margin was driven by higher expenses.
Is New 90 Day High Low • Jan 25New 90-day low: CN¥5.02The company is down 3.0% from its price of CN¥5.19 on 28 October 2020. The Chinese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 25% over the same period.
Is New 90 Day High Low • Dec 14New 90-day high: CN¥6.06The company is up 14% from its price of CN¥5.32 on 16 September 2020. The Chinese market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 6.0% over the same period.
Is New 90 Day High Low • Nov 18New 90-day high: CN¥5.71The company is up 2.0% from its price of CN¥5.62 on 20 August 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 5.0% over the same period.
Reported Earnings • Nov 01Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥627.2m, up 19% from the prior year. Total revenue was CN¥10.5b over the last 12 months, up 2.7% from the prior year.
Is New 90 Day High Low • Sep 24New 90-day low: CN¥5.18The company is down 2.0% from its price of CN¥5.26 on 24 June 2020. The Chinese market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 21% over the same period.